Clinician scientist at @vallhebron Phase 1 and Cancer Genomics Group @VHIO. Former med onc fellow at @pmcancercentre, Phase1/Head and Neck, biomarkers.
Joined March 2020
- Tweets194
- Following430
- Followers329
- Likes505
Pinned Tweet
Thank you @myESMO for highlighting our recent publication in @eClinicalMed unveiling dowstream effects of performing #NGS in pts with advanced solid tumors enrolled in OCTANE. Very nice summary!
👇
esmo.org/oncology-news/an-in…
👇
thelancet.com/journals/eclin…
AHernando_Calvo retweeted
🗞️ In @LancetRH_Europe: VHIO professionals @piris_alejandro, Irene Braña and @AhernandoCalvo have contributed, through @PRIMEROSE_EU, to a review on the key challenges and next steps needed to ensure equitable access to precision cancer medicine in Europe.
➡️ linke.to/TheLancetRegEuVHIO
#UITM @CaixaResearch
Conclusions: MD-PhD training generates sustained academic productivity and leadership, but structural barriers threaten retention of graduates within clinical-academic careers. Protecting research time, stabilising funding and pay, and reducing geographic instability needed
Clinician scientist training is under threat: this analysis reviews the outcomes of a 25 yearcohort of the UCL MB-PhD program from 1995 : a long-term investment in the clinician-scientist workforce medRxiv medrxiv.org/content/10.64898…
AHernando_Calvo retweeted
🇪🇺 @piris_alejandro and Alberto Hernando Calvo represented #VHIO at the European Parliament, invited by @CGIclinics in recognition of VHIO’s contribution to #JAPCM and its pilot project within the Supranational Molecular Tumor Board initiative. 🔬💡
@EU_Health
Happening now at TAT 2026 @myESMO . Parp inh and synthetic lethality🧬Great presentations by Victoria Rodriguez and Xavi Maldonado from @vallhebron @VHIO
AHernando_Calvo retweeted
🚀 We took part in the kick-off meeting of the Joint Action on Personalised Cancer Medicine (JA PCM), a new EU initiative to expand access to personalised cancer care across Europe.
🔬 As partners, we lead a pilot to create a supranational Molecular Tumor Board for rare and complex cases and work on harmonising data collection.
🌎 Together, advancing personalised cancer medicine.
AHernando_Calvo retweeted
Phase 1 Study (NCT04429542): Ficerafusp alfa with/without pembrolizumab in advanced solid tumors. brnw.ch/21wXRcH
AHernando_Calvo retweeted
Thanks for the mention @CataniGreta! A true pleasure working with you under the expert guidance of @AhernandoCalvo and the rest of the @VHIO team. Thrilled to share our review on biomarkers in early-phase immunotherapy trials!
Our review on biomarker enrichment in early-phase immunotherapy trials is out in @FrontiersIn
Grateful to collaborate with @dmorchon95 and especially for the mentorship and guidance of @AhernandoCalvo, who made this work possible
doi.org/10.3389/fimmu.2025.1…
AHernando_Calvo retweeted
Our review on biomarker enrichment in early-phase immunotherapy trials is out in @FrontiersIn
Grateful to collaborate with @dmorchon95 and especially for the mentorship and guidance of @AhernandoCalvo, who made this work possible
doi.org/10.3389/fimmu.2025.1…
Happy to see this finally out! Humbled by the support from my former mentors at @pmcancercentre and Marc Oliva at @ICO_oncologia. An international collaboration including ultra-rare sinonasal cancers.
📌Now that we understand the prognostic factors, let's find druggable targets
This Post is from an account that no longer exists. Learn more
AHernando_Calvo retweeted
Check out our latest review in collaboration with @VHIO @vallhebron team during my observership, funded by a @_SEOM grant. Congrats to first co-author @CataniGreta and special thanks to @AhernandoCalvo for the mentorship
@IBSAL_IIS @IAF_Fleming @IJMS_MDPI
mdpi.com/3343834
AHernando_Calvo retweeted
@drenriquegrande !! 11 años avanzando en la oncología de precisión y aplicando la genómica al día a día! Un lujo contar con un panel de ponentes brutal !! Pero dejad que me 🤤 con mis amigos del @VHIO que se han salido como siempre! @rdienstmann @JHernando3 @AhernandoCalvo 🙌🏼👏🏼
AHernando_Calvo retweeted
🔬Esta semana hemos sabido que un estudio de @Genomicslab_ y la #UITM-@CaixaResearch del VHIO muestra que combinar la firma génica #VIGex con #biopsialíquida mejora la predicción de respuesta a inmunoterapia en tumores sólidos avanzados.
➕linke.to/VIGexVHIO24
#CAIMI #DIAMAV
📸 María Vila-Casadesús, @ElenaGarralda, @AnaVivancosVHIO y @AhernandoCalvo
AHernando_Calvo retweeted
🧑🏻⚕️ @AhernandoCalvo , @vallhebron, #UITM @CaixaResearch i @Genomicslab_ VHIO, rep una beca @GileadSciences per validar l’eina #VIGex com a biomarcador de resposta a la immunoteràpia en assajos de fase primerenca
👏 Enhorabona ‼️
➕ linke.to/GileadGrant_cast
📍Happy to share this publication @JCOPO_ASCO validating VIGex signature in the INSPIRE trial. Improved predictive performance for IO benefit was observed with VIGex+ctDNA dynamics in this international collaboration 🇨🇦 🇪🇸@pmcancercentre @VHIO @vallhebron ascopubs.org/doi/10.1200/PO.…
Phase II, open-label, randomized trial of durvalumab with olaparib or cediranib in pts with pMMR CRC or pancreatic cancer at @pmcancercentre. Mentorship from Aaron Hansen and @lillian_siu and support from @PughLab @bhaibeka labs @OICR_news and others!
doi.org/10.1016/j.clcc.2024.…
AHernando_Calvo retweeted
Findings from a first-in-human phase I study investigating IBI363 - @ESMO
@AhernandoCalvo @vallhebron @VHIO @pmcancercentre
oncodaily.com/84097.html
#Cancer #ESMO #ESMODailyReporter #ESMOVirtualPlenary #Melanoma #OncoDaily #Oncology
📍Stay tuned for today´s session with both clinical insights and AACR expert commentary
Missed yesterday's session?
👉 Stay up to date with innovative #immunotherapy approaches and engage with the panel of expert presenters by submitting your questions live. #ESMOVirtualPlenary
🔗 ow.ly/gJCL50SgEow
AHernando_Calvo retweeted
#ESMOVirtualPlenary: Safety & efficacy of a PD-1/IL-2 bispecific antibody fusion protein show proof-of-concept on its capacity to overcome resistance to #immunotherapy in pre-treated pts & some populations w/ poor prognosis.
#ESMODailyReporter
👉 ow.ly/c59250SiccM
AHernando_Calvo retweeted
Almost starting #ASCO24, and receiving the news that our review in new therapies (ADC, BsAbs) for H&N SCC and nasopharyngeal carcinoma is finally published in Cancer Treatment Reviews! Congrats to all co-authors! 👏#HNCSM @royalmarsdenNHS @VHIO
authors.elsevier.com/a/1jA%7…
Happy to share our last review in Cancer Treatment Reviews. Big support from @AliceRossiMD , Maria Vieito, Emile Voest @NKI_nl and Elena Garralda @VHIO
🙌Exciting times for tumor agnostic therapies but also many challenges lying ahead
cancertreatmentreviews.com/a…